Search

everythinglearnresearchcommunity

for

Search:↓

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

JAK inhibitors help hair growth by boosting beta-catenin activity in hair root cells.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

EGFR inhibitors can cause skin issues, and managing these is important for treatment success.

Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.

Ruxolitinib effectively regrows hair in most patients with severe hair loss.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.

Ritlecitinib shows promise for hair regrowth in alopecia areata patients.

Finasteride increases P-glycoprotein activity in the liver and kidney.

A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.

JAK inhibitors are effective and safe for treating severe alopecia areata.

Vismodegib is effective for basal cell carcinoma but has severe side effects.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.

Ruxolitinib treatment may cause eyelash growth.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Combining irinotecan and cetuximab is effective for some metastatic colorectal cancer patients but often causes manageable skin issues.

Tofacitinib may effectively treat folliculitis decalvans.

JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.

Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Metformin may help treat neuroendocrine tumors.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.